Related Experiment Video
Updated: Aug 7, 2026
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
Long-term hydroxyurea treatment in young sickle cell patients
M Maier-Redelsperger1, D Labie, J Elion
1Service d'Hématologie Biologique et INSERM U 458, hôpital Tenon, Paris, France.
Insights
Hydroxyurea treatment significantly improves sickle cell disease in children, reducing crises and transfusions. Fetal hemoglobin levels increase sustainably with minimal side effects, suggesting further large trials may not be needed.
Area of Science:
- Hematology
- Pediatric Medicine
- Pharmacology
Background:
- Hydroxyurea is a proven treatment for sickle cell disease in adults.
- Pediatric trials for hydroxyurea have been limited in scope and design.
- Children with sickle cell disease show promising responses to hydroxyurea therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of hydroxyurea in pediatric sickle cell disease patients.
- To assess the impact of hydroxyurea on clinical outcomes and hematological parameters in children.
- To determine the sustained effects and side effect profile of hydroxyurea in this population.
Main Methods:
- Review of small-scale trials and existing data on hydroxyurea in children.
- Analysis of therapeutic schedules, clinical improvements, and hematological changes.
- Assessment of follow-up data ranging from 6 to 59 months.
Main Results:
- Children demonstrated rapid clinical improvement, with decreased vaso-occlusive crises and acute chest syndromes.
- Significant increases in fetal hemoglobin, mean corpuscular volume, and total hemoglobin were observed across patients.
- Sustained elevation of fetal hemoglobin and a low incidence of side effects were noted, exceeding adult responses.
Conclusions:
- Hydroxyurea is an effective treatment for pediatric sickle cell disease, offering substantial clinical benefits.
- The sustained increase in fetal hemoglobin and favorable safety profile in children are notable.
- Further large-scale, placebo-controlled studies in children may be unnecessary; guidelines for use are needed.
Abstract:
Hydroxyurea is the first drug that, under well-organized, large-scale trials in adults, has shown a beneficial effect on the clinical course of sickle cell disease. Several small-scale trials have been conducted in children, but they used different therapeutic schedules, and only one was a single-blind crossover trial. Still, children are clearly good responders to the treatment because a rapid clinical improvement was observed, with decreased frequencies of vaso-occlusive crises, acute chest syndromes, and transfusion requirements. Despite large interindividual variations, virtually all the children studied increased their fetal hemoglobin, mean corpuscular volume, and total hemoglobin. Follow-up varied from 6 months to 59 months. More than in adults, the fetal hemoglobin increase was sustained, and few side effects were observed. Large-scale, placebo-controlled studies seem no longer needed. Guidelines concerning patient selection, dosing schedules, and monitoring protocols as well as exhaustive registries for the detection of long-term side effects are necessary.
More Related Videos
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:24Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...